Search
Roxatidine acetate
go.drugbank.com/drugs/DB08806InvestigationalRoxatidine acetate is a specific and competitive H2 receptor antagonist. It is currently approved in South Africa under the tradename Roxit.
Metergoline
go.drugbank.com/drugs/DB13520Approved[A27181] Its use has been studied in various clinical settings such as a treatment for seasonal affective disorder, prolactin hormone regulation due to its inhibitory effect on prolactin release,[A27182
Bromazepam
go.drugbank.com/drugs/DB01558ApprovedIllicitIt is a Schedule IV drug in the U.S. and Canada and under the Convention on Psychotropic Substances. It is a intermediate-acting benzodiazepine.
Products: BROMAZEPAM N&PRusalatide
go.drugbank.com/drugs/DB05309InvestigationalTP508 is a non-proteolytic synthetic peptide representing the portion of human thrombin originally identified as the fibroblast high-affinity receptor binding domain.
Estramustine phosphate
go.drugbank.com/drugs/DB14674ApprovedA nitrogen mustard linked to estradiol, usually as phosphate; used to treat prostatic neoplasms; also has radiation protective properties.
NCX 1022
go.drugbank.com/drugs/DB05410ExperimentalNCX is an NO-releasing derivative of hydrocortisone.
Cry5B
go.drugbank.com/drugs/DB17783ExperimentalCry5B is a pore-forming crystal protein produced by and derived from the soil bacterium _Bacillus thuringiensis_.
AZD-8186
go.drugbank.com/drugs/DB15029Investigationalinvestigation in clinical trial NCT03218826 (PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by
2X-121
go.drugbank.com/drugs/DB16063Investigational2X-121 is under investigation in clinical trial NCT03562832 (Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the